Bibliography
- Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90
- Ljungberg B, Campbell SC, Choi HY, et al. The epidemiology of renal cell carcinoma. Eur Urol 2011;60:615-21
- Gupta S, Spiess PE. The prospects of pazopanib in advanced renal cell carcinoma. Ther Adv Urol 2013;5:223-32
- Ljungberg B, Bensalah K, Bex A, et al. Guidelines on renal cell carcinoma. Available from: http://www.uroweb.org/gls/pdf/10_Renal_Cell_Carcinoma_LR.pdf [Last accessed 21 January 2014]
- US Food and Drug Administration. Votrient (pazopanib) full prescribing information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022465s011lbl.pdf [Last accessed 21 January 2014]
- European Medicine Agency. Votrient 200 mg and 400 mg film coated tablets. Available from: http://www.medicines.org.uk/emc/medicine/23148/SPC/Votrient+200+mg+and+400+mg+film+coated+tablets/ [Last accessed 21 January 2014]
- Rini B, Al-Marrawi MY. Pazopanib for the treatment of renal cancer. Expert Opin Pharmacother 2011;12:1171-89
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. 2012. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site [Last accessed 21 January 2014]
- Posadas EM, Limvorasak S, Sharma S, et al. Targeting angiogenesis in renal cell carcinoma. Expert Opin Pharmacother 2013;14:2221-36
- Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54
- Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65
- Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009;10:992-1000
- Ravaud A, Gross-Goupil M, Bellmunt J. Combination therapy in metastatic renal cell cancer. Semin Oncol 2013;40:472-81
- Hutson TE, Davis ID, Machiels JP, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010;28:475-80
- Hainsworth JD, Rubin MS, Arrowsmith ER, et al. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial. Clin Genitourin Cancer 2013;11:270-5
- Bukowski RM, Yasothan U, Kirkpatrick P. Pazopanib. Nat Rev Drug Discov 2010;9:17-18
- Santos N, Wenger JB, Havre P, et al. Combination therapy for renal cell cancer: what are possible options? Oncology 2011;81:220-9
- Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf 2013;36:491-503
- Sanford M, Keating GM. Pazopanib: in advanced renal cell carcinoma. BioDrugs 2010;24:279-86
- Shibata S, Chung V, Synold TW, et al. Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 2013;19:3631-9
- Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8
- Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013;49:1287-96
- Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369:722-31
- Escudier B, Porta C, Bono P, et al. A randomized, controlled, double-blind, crossover trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma (PISCES Study). J Clin Oncol 2014. [ Epub ahead of print]
- Motzer R, Hutson T, Reeves J, et al. Randomized, open-label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients withmetastatic renal cell carcinoma (mRCC): results of the COMPARZ trial. Ann Oncol 2012;23:A2325
- Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009;15:4220-7
- Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499:43-9